CardioVascular BioTherapeutics Inc.

CORPORATE PROFILE

Recent Price: As of April 28, 2005.	$8.52	Stock Symbol:	CVBT
12-Month Range:	$5.50-$15.20	Shares Outstanding As of March 31, 2005	120.1 Million shares
Market Cap: As of April 14, 2005.	$ 974.48 Million	Approximate Float	22 Million shares

Corporate Overview

CardioVascular BioTheraputics (Cardio) is a biopharmaceutical company headquartered in Las Vegas, Nevada with research, development and manufacturing facilities in Irvine, California. The company is solely focused on introducing new therapies for cardiovascular disease. According to the American Heart Association over 38% of all deaths in the United States per year are a result of cardiovascular disease. The majority of these deaths occur when a blood vessel becomes blocked and the tissue which it supplies dies, whether it is a blocked coronary artery in the heart, a blocked cerebral artery in the brain or a blocked femoral artery in the leg. New therapies that can stimulate the growth and development of new and permanent blood vessels could have a major impact on the treatment and curing of diseases resulting from blocked blood vessels.

Cardio is actively developing a potent growth factor, Cardio Vascu-Grow™, which stimulates the growth of new blood vessels, a biological process termed "angiogenesis". This growth factor is being tested in a wide variety of human diseases that would benefit from increased angiogenesis including coronary artery disease, stroke, and peripheral vascular disease of the legs and wound healing. The company has already performed extensive clinical studies in patients with coronary artery disease with excellent results and plans to begin human testing this year in diabetics with wound healing deficiencies and vascular disease in their legs. Animal studies that mimic these human conditions were all highly successful and indicated that Cardio Vascu-Grow™ could cure and not merely treat the symptoms of these ailments. The large number of patients that suffer from these cardiovascular diseases make each of these medical indications a potential multi-billion dollar market opportunity for Cardio Vascu-Grow™ if approved by the FDA.

In addition, CVBT has identified over 12 additional medical indications for Cardio Vascu-Grow™ and has initiated animal testing in these areas. These new indications, again, are a direct result from a decreased or blocked blood supply to a target area or organ and include such ailments as chronic back pain, intestinal ischemia and hearing loss. There are large numbers of patients that suffer from these diseases and to the Company's knowledge there is currently no medical treatment available that can reverse the blood vessel blockages that cause these diseases.

Corporate History

Although Cardio was established in 1998, the work with Cardio Vascu-Grow™ began in the early 1990's with a breakthrough therapy developed by Dr. Thomas-Joseph Stegmann and his team of German heart researchers in Fulda, Germany. Dr. Stegmann, a co-founder of CVBT, demonstrated in two landmark studies the potential of Cardio Vascu-Grow™ to cure coronary artery disease.

Management team

Cardio has a seasoned team of business professionals and drug development executives leading its efforts to commercialize Cardio Vascu Grow™. The executive team includes members with decades of experience in managing both privately-held and publicly-traded companies. The scientific executive staff includes individuals with proven drug-development track records over many years in the pharmaceutical industry.

The Impact of Cardio Vascu-Grow™ in the Human Heart



The images above show a human heart both untreated (left) and treated (right) with Vascu-Grow™.
The above photo of an angiogram obtained from a patient treated with Cardio Vascu-Grow™ shows the promise of this treatment where a dense growth of new blood vessels can be seen in the patient's heart where the drug was injected.

Daniel C. Montano – Co-Founder, Chairman, President & CEO

Thomas Stegmann, MD
Co-Founder & Chief Medical Officer

John (Jack) William Jacobs Ph.D.
Chief Operating Officer and Chief Scientific Officer

Mickael A. Flaa, CPA
Chief Financial Officer

LANDMARK STUDIES USING CARDIO VASCU-GROW™

The potential of Cardio Vascu-Grow™ (human FGF-1) as a new treatment for Coronary Heart Disease was demonstrated by Dr. Thomas Stegmann and his associates in two separate clinical trials performed in Germany. A total of 40 no-option heart patients received injections of Cardio Vascu-Grow™ into their hearts and the clinical results from these studies, published in internationally-recognized medical journals was a resounding success. The two studies demonstrated that Cardio Vascu-Grow™ was a safe and efficacious treatment for severe coronary artery disease. All patients demonstrated new blood vessel growth at the site of injection which persisted for over 3 years. In addition the following results were observed.

- 80% of patients showed a significant improvement in their stress exercise test.
- Perfusion of the heart under stress showed a 5-fold increase in the SPECT perfusion score.
- No significant adverse safety effects of the therapy
- Importantly, 90% patients had an improvement in their dominant clinical symptom, angina or chest pain. During the stress exercise test, angina was either completely absent, or began at much higher levels of exertion.

To read the detailed clinical studies, visit the company website at www.cvbt.com.

These results led to Dr. Stegmann joining with a team of experienced pharmaceutical researchers and business executives for the purpose of commercializing Cardio Vascu-Grow™ as a new treatment for the millions of patients who suffer from some form of cardiovascular disease.

U.S. CLINICAL STUDIES

Cardio is well along the pathway of commercializing Cardio Vascu-Grow™ as it confirms Dr. Stegmann's previous findings in its ongoing FDA-authorized clinical trials. Six U.S Medical Centers are participating in the current studies as different doses of Cardio Vascu-Grow™ are examined for their effect to stimulate new blood vessel growth in the hearts of no-option patients. Even at the lowest dose tested Cardio Vascu-Grow™ was shown to be safe and efficacious and these initial results were highlighted in a national news segment on ABC Nightly News. In addition to our ongoing heart study, CVBT plans to begin new clinical trials this year for other serious diseases characterized by blocked arteries resulting in tissue ischemia.

CLINICAL DEVLOPMENT PROGRAMS

CARDIO has active pre-clinical and clinical development programs ongoing with Cardio Vascu-Grow™ in the following medical indications:

I. Muscle Tissue Indications

1.1 No-Option Heart Patients
1.2 Adjunct Treatment in Heart Patients undergoing Bypass Surgery
1.3 Severe Angina Pectoris (surgical administration)
1.4 Peripheral Vascular Disease (Legs) in Diabetics
1.5 Chronic Back Pain
1.6 Catheter-based Delivery into the Heart in Angina Patients

II. Wound Healing Indications

2.1 Diabetic Ulcers
2.2 Bed Sores
2.3 Surgical Wounds and Organ Transplants

III. Nerve Tissue Indications

3.1 Stroke
3.2 Diabetic Peripheral Nerve Pain
3.3 Spinal Cord Injury
3.4 Parkinson's Disease
3.5 ALS (Lou Gehrig's Disease)
3.6 Multiple Sclerosis

IV. Kidney

4.1 Ischemic Kidney Disease

V. Intestine

5.1 Intestinal Ischemia
5.2 Pancreatitis

VI. Other

6.1 Corneal Repair

For more information:
Investor Awareness
Tony Schor/ Lindsay Kenoe
847-945-2222
www.investorawareness.com

CardioVascular BioTherapeutics
pr@cvbt.com
or
www.cvbt.com
949-823-1028